Five Prime protein beefs rep via GSK license deal; respiratory bid chuffs on
By Randy Osborne
Friday, July 15, 2016
Five Prime Therapeutics Inc.'s respiratory diseases pact with GSK bore fruit, putting $1.5 million in the pocket of the former by way of a license option fee, with the promise of more if the protein on the table hits milestones.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.